The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.

Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal ...

HHS may reconsider blocked 340B rebate pilot after courts halt the program, signaling potential changes for drug discount policies in 2024.

An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers. At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program ...

On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district ...

On January 15, 2026, President Trump released a one-page health policy framework. Among other things, the document includes ...

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

The Trump administration has signaled plans to drop its appeal of a court order that blocked a pilot from changing payment terms for the 340B drug discount program.

Health Affairs' Rob Lott interviews Sayeh Nikpay of the University of Minnesota about her recent paper exploring how The Medicaid Drug Rebate Program and the 340B Program interact in ways that can ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...